Ficha del valor · trimestre archivado
AKRO
Akero Therapeutics, Inc. · Healthcare · Biotechnology
13Tenedores rastreados
+1Δ titulares
19.73MAcciones mantenidas
$798.59MValor declarado
+1Nuevas posiciones
−0Cierres
Señales de momentum (gestores comparables):
amplitud de titulares +8.3% ·
flujo de acciones +7.6% ·
nuevas posiciones netas +7.7%
— fórmula
Acumulación amplia — aumento de acciones entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q1 2025
Participación a lo largo del tiempo
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2025 | 18 | 0 | 30.14M | $1.43B | +1 | −1 |
| Q2 2025 | 15 | -1 | 29.65M | $1.58B | — | −1 |
| Q1 2025 | 13 | +1 | 19.73M | $798.59M | +1 | — |
| Q4 2024 | 12 | +3 | 18.33M | $510.05M | +3 | — |
| Q3 2024 | 8 | 0 | 15.01M | $430.62M | +1 | −1 |
| Q2 2024 | 8 | — | 11.90M | $279.29M | — | — |
Quién lo tiene en cartera · Q1 2025
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 4.82M | +11.5% | $195.00M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 4.82M | +11.5% | $195.00M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | State Street Global Advisors ✦ (pasivo) | 2.49M | +6.8% | $100.99M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 1.91M | +40.9% | $77.29M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 1.91M | +40.9% | $77.29M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | Geode Capital Management ✦ (pasivo) | 1.75M | +12.2% | $70.82M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Geode Capital Management ✦ (pasivo) | 1.75M | +12.2% | $70.82M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Marshall Wace ✦ | 1.61M | +484.5% | $65.09M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 17 | Marshall Wace ✦ | 1.61M | +484.5% | $65.09M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 508.34K | -43.5% | $20.58M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 19 | Millennium Management ✦ | 230.86K | +1279.5% | $9.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 199.00K | +856.7% | $8.06M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | Adage Capital Partners ✦ | 195.00K | Nuevo | $7.89M | 0.0% | New | 1 | SEC ↗ |
| 22 | Two Sigma Investments ✦ | 62.02K | -51.3% | $2.51M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 12.16K | -66.0% | $492,196 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Adage Capital Partners | $7.89M | 0.0% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Frecuentemente cotituladas
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Procedencia: Participación a partir de posiciones en acciones ordinarias de 13F procesadas (universo rastreado, conjuntos comparables para cambios); filas de iniciados de los Formularios 3/4/5; participaciones de los Schedules 13D/13G; cada filing enlaza con su original en SEC EDGAR.
Período de reporte: Q1 2025 ·
Metodología ·
Obtener esto a través de la API